We have identified Pcdhg as a key factor in vascular inflammation, particularly in endothelial cells, and developed a potential treatment approach using antibodies to block its activity. In preclinical studies with mice, blocking Pcdhg significantly reduced atherosclerosis and improved the quality of arterial plaques. This suggests that targeting Pcdhg could be an effective strategy for treating a range of cardiovascular conditions without weakening the body’s ability to defend against infections.